⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

May 1, 2024Open Access

Supplementary Figure 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study

Tobias Else Eric Jonasch Othon Iliopoulos Kathryn E. Beckermann Vivek Narayan Benjamin L. Maughan Stéphane Oudard Jodi K. Maranchie Ane B. Iversen Cynthia M. Goldberg Wei Fu Rodolfo F. Perini Yanfang Liu W. Marston Linehan Ramaprasad Srinivasan

View Full Paper

Ask AI

Bookmark

Share

Abstract

Supplementary Figure 1. Efficacy of belzutifan monotherapy for all pancreatic lesions. A, Kaplan-Meier curve of progression-free survival for pancreatic lesions. B, Spider plot showing change from baseline over time in size of target pancreatic lesions.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Else et al. (2024) studied this question.

synapsesocial.com/papers/68e6c4bab6db643587643b25 https://doi.org/10.1158/1078-0432.25728553

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 1 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study2024
2Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study2024
3Supplementary Figure 2 from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study2024
4Data from Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study2024
5Belzutifan for von Hippel–Lindau Disease: Pancreatic Lesion Population of the Phase 2 LITESPARK-004 Study2024 · 33 citations

Abstract CT221: Belzutifan, a hypoxia-inducible factor-2α (HIF-2α) inhibitor, for von Hippel-Lindau (VHL) disease-associated neoplasms: Long-term results of the phase 2 LITESPARK-004 study2024
Extended follow-up (6 years) of the phase 2 LITESPARK-004 study of belzutifan in participants with von Hippel-Lindau disease–associated neoplasms.2026
Phase 2 trial of belzutifan in participants from China and Japan with von Hippel-Lindau disease-associated tumors: Results from LITESPARK-015 cohort B1.2026